Global 
Australia 
België 
Deutschland 
España 
France 
Ireland 
Italia 
Luxembourg 
Nederland 
Österreich 
Portugal 
Россия 
Schweiz 
United Kingdom 
Quoi de neuf ?
Quoi de neuf en ce moment chez Dr. Falk Pharma AG ? Vous trouverez les actualités, les communiqués de presse, les appels à études et les évènements à venir dans notre Newsroom et sur les réseaux sociaux.
Positive results from pivotal phase 3 trial on norucholic acid in PSC
The results of the 96-week analysis of the NUC-5 trial will be presented at 2025 EASL Congress in Amsterdam
Today is World Liver Day!
Did you know that our first product back in 1960 was a therapeutic drug for the liver?
Back to the Future – Unleashing the Power of Established Drugs
Lunch satellite symposium on 21.02.2025 during the Congress of ECCO in Berlin
Dr. Falk Pharma acquires Kynos Therapeutics
...adding acute pancreatitis as a therapeutic focus and further strengthening its development portfolio
New Addition to the Management Board
The new Technical Operations business unit will be headed up by Dr. Andreas Rascher
Eating should be a pleasure
What does it feel like to eat when you know that each bite will hurt when swallowing?
![[Translate to French:]](/fileadmin/FP_HQ/newsroom/20230405_PR_Change-in-Management/teaser_Management-change-DrFalkPharmaGmbH.jpg "[Translate to French:]")
Management change at Dr. Falk Pharma GmbH
Kai Pinkernell takes over as Managing Director Science & Innovation.
![[Translate to French:]](/fileadmin/FP_HQ/newsroom/20230228_RareDiseaseDay/teaser_Rare-Disease-Day-2023.jpg "[Translate to French:]")
Rare Disease Day
As the experts in digestive and metabolic medicine, our focus is also on rare diseases.
Initiation of Phase II Study of naronapride in patients with gastroparesis
Renexxion Ireland and Dr. Falk Pharma announce that the first patient has been treated
Collaboration and Licensing Agreement with Takeda and Zedira
To Develop First-in-Class Celiac Disease Therapy
NAFLD: Phase 2a proof of concept study of ZED1227
Dr. Falk Pharma and Zedira announce trial start for the treatment of non-alcoholic fatty liver disease. First patient enrolled in April.
Have difficulty swallowing food?
Difficulty swallowing and pain while eating may be warning signs of eosinophilic esophagitis (EoE). The first EoE Day will be held on May 22, 2022.
Future starts here
Plans for the future Falk Campus in Freiburg-Nord finalized.